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Abstract
Background: Transparency in quality of care (QoC) is stimulated and hospitals are compared and judged on the
basis of indicators of performance on specific treatment targets. In patients with chronic kidney disease, QoC
differed significantly between hospitals. In this analysis we explored additional parameters to explain differences
between centers in attainment of parathyroid hormone (PTH) treatment targets.
Methods: Using MASTERPLAN baseline data, we selected one of the worst (center A) and one of the best (center
B) performing hospitals. Differences between the two centers were analyzed from the year prior to start of the
MASTERPLAN study until the baseline evaluation. Determinants of PTH were assessed.
Results: 101 patients from center A (median PTH 9.9 pmol/l, in 67 patients exceeding recommended levels) and
100 patients from center B (median PTH 6.5 pmol/l, in 34 patients exceeding recommended levels), were included.
Analysis of clinical practice did not reveal differences in PTH management between the centers. Notably,
hyperparathyroidism resulted in a change in therapy in less than 25% of patients. In multivariate analysis kidney
transplant status, MDRD-4, and treatment center were independent predictors of PTH. However, when MDRD-6
(which accounts for serum urea and albumin) was used instead of MDRD-4, the center effect was reduced.
Moreover, after calibration of the serum creatinine assays treatment center no longer influenced PTH.
Conclusions: We show that differences in PTH control between centers are not explained by differences in
treatment, but depend on incomparable patient populations and laboratory techniques. Therefore, results of
hospital performance comparisons should be interpreted with great caution.
Keywords: Chronic kidney disease, Parathyroid hormone, Quality of care, Treatment targets
Background
Patients with chronic kidney disease (CKD) are at
increased risk of developing cardiovascular disease [1-3].
Multiple traditional and non-traditional risk factors con-
tribute to this increased cardiovascular risk. In recent
years an important role of disturbances in bone and
mineral metabolism has been established [4-8]. Patients
with CKD are characterized by variable degrees of vita-
min D deficiency, hyperparathyroidism, hypercalcemia
and hyperphosphatemia. These abnormalities contribute
to soft tissue and vascular calcification, and ensuing car-
diovascular injury [9]. Parathyroid hormone (PTH) level
is already elevated in patients with mild CKD and preva-
lence of hyperparathyroidism rises substantially when
glomerular filtration rate (GFR) decreases [10,11]. Con-
sequently, PTH is one of the most deviant laboratory
parameters in CKD patients.
The 2003 K/DOQI clinical practice guideline
addressed the treatment of CKD-bone and mineral
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disorder and defined treatment targets for calcium,
phosphate, and PTH [12]. Newer guidelines with differ-
ent targets were recently published [13]. Defining treat-
ment goals is only one aspect of quality of care (QoC).
Health care authorities, health insurance companies, as
well as organizations of health care professionals have
introduced benchmarking as a way to compare and im-
prove QoC [14-16]. Treatment centers are asked to pro-
vide figures on treatment targets, complication rates,
and survival rates. Hospital performance is determined
on the basis of these figures.
Nevertheless, implementation of guidelines is rather
difficult and treatment goals are often not met [17-19].
We recently showed that in CKD patients QoC, defined
as attainment of treatment targets, differed significantly
between treatment centers [20,21]. Differences were not
explained by available patient characteristics. We
hypothesized that detailed comparison of all aspects of
treatment in these centers may help to define para-
meters that are associated with QoC, and eventually im-
prove performance. In the present study, we compared
two centers that differed in the attainment of the PTH
treatment goal in CKD patients and explored possible
explanations.
Methods
The MASTERPLAN (Multifactorial Approach and Su-
perior Treatment Efficacy in Renal Patients with the Aid
of Nurse practitioners) study [Trial registration ISRCTN
registry: 73187232] is a randomized controlled trial con-
ducted in nine centers with a nephrology department in
The Netherlands, evaluating the added value of nurse
practitioner care in reducing cardiovascular events and
attenuating kidney function decline in patients with
prevalent CKD. Rationale and design have been pub-
lished elsewhere [22,23]. Ethics committee approval was
obtained as well as written informed consent of all parti-
cipants. Between April 2004 and December 2005,
patients were enrolled.
We recently analyzed baseline data and evaluated
QoC, defined as achievement of treatment goals. We
noted significant differences between treatment centers
for various treatment goals such as blood pressure, chol-
esterol, and PTH [20]. In the present study we focused
on management of PTH and selected one of the worst
(center A) and one of the best (center B) performing
hospitals. Study design can be described as a nested case
control study (on hospital level).
PTH is one of the quality indicators of the Dutch Fed-
eration of Nephrology. It is, therefore, a usual quality of
care target.
PTH was defined as exceeding recommended levels
if > 7.7 pmol/l in patients with estimated glomerular fil-
tration rate (eGFR) ≥ 30 ml/min/1.73 m2, if > 12.1 pmol/l
in patients with eGFR 15–29 ml/min/1.73 m2, and if >
33.0 pmol/l in patients with eGFR < 15 ml/min/1.73 m2,
based upon the then available CKD-bone and mineral
disorder guidelines [12].
We used the baseline clinical and laboratory data of
the patients as available according to the MASTER-
PLAN study protocol [23]. We retrieved additional data
from the medical records, using a form, specifically
addressing known determinants of PTH [24,25] and
characteristics of treatment in the year before the
baseline MASTERPLAN visit (number of patient visits,
number of laboratory tests performed, adjustment of
treatment affecting PTH levels). The additional data col-
lection for the present study, was possible on the basis
of the before mentioned ethics committee approval and
informed consent.
Initially eGFR was calculated using the abbreviated
MDRD formula [26] (MDRD-4). In addition the six-
variable MDRD formula [27] (MDRD-6) and the CKD-
EPI equation [28] were used in order to achieve a more
accurate estimation of the GFR. We also compared the
serum creatinine assays between the hospitals. The hos-
pitals used different Jaffé methods to measure serum
creatinine. Both methods were compared to one enzym-
atic method (Roche Diagnostics). The following equa-
tions were developed. For center A: enzymatic
creatinine = 1.266 x Jaffé creatinine - 29. For center B:
enzymatic creatinine = (Jaffé creatinine - 28) / 0.93.
In center A PTH was measured by an immunolumino-
metric assay (Nichols Institute, San Clemente, USA). In
center B an immunoradiometric assay from the same
manufacturer was used. Since both methods use anti-
bodies directed against the same regions of the PTH
molecule and reference values are similar we con-
sider the methods comparable. This is confirmed by
Souberbielle et al., as they found no significant dif-
ference in measured PTH concentration between
both methods [29].
Proteinuria and smoking data were missing in two
patients, income data were missing in 34 patients. Two
analyses were performed: one without cases with missing
values and another in which missing data were imputed
by single imputation. In proteinuria and income median
values were imputed, in smoking the mode was used.
The presented data are after imputation.
In the analysis of characteristics of treatment in the
year before MASTERPLAN baseline (management of
hyperparathyroidism), we excluded patients who were
under specialist physician care for less than six months
prior to study enrollment. We used the six month criter-
ion since we aimed to evaluate differences in QoC be-
tween hospitals and not between general practitioners.
Characteristics are given for the study population by
treatment center and expressed as means (standard
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deviation) or proportions. Medians [interquartile range]
are presented for variables with a skewed distribution.
Differences between the two treatment centers were
studied using an independent-samples T test for con-
tinuous variables and a chi-square test for categorical
variables. The natural logarithm (Ln) of PTH had a nor-
mal distribution and was used for correlation analyses.
Correlation with several potential determinants was
studied using a Pearson correlation coefficient for con-
tinuous variables and a Spearman’s rho correlation coef-
ficient for categorical variables. If necessary, the Ln of
continuous variables was used to obtain a normal distri-
bution. Multivariate analyses using stepwise backward
linear regression models were performed to find deter-
minants of PTH. Variables with univariate associations
and potential confounders were included. Criteria for ex-
clusion and re-inclusion were p ≥ 0.10 and p < 0.05 re-
spectively. Variables were excluded from the final
multivariate model if they did not contribute consider-
ably to the explained variance (change in R2 < 5%).
Multivariate Poisson regression models were used to
construct prediction models for meeting the PTH treat-
ment target. Variables with univariate associations were
included. All p-values were two-sided, and for all tests
p-values less than 0.05 were considered to indicate stat-
istical significance. The univariate analyses were per-
formed with SPSS 16.0 (SPSS Inc., Chicago, USA). The
multivariate analyses were performed with Stata 10.1
(StataCorp LP, College Station, USA).
Results
Medical records of 101 patients from center A and 100
patients from center B were studied. Center A is a uni-
versity clinic with 953 beds and center B is a non-
university clinic with 653 beds. Both centers are teaching
hospitals that offer a full range of nephrology treatment
including kidney replacement therapy and are involved
in the care of kidney transplant recipients. The two cen-
ters are located in the same region of The Netherlands.
Characteristics of the study population are given in
Table 1. The majority of patients were male (71%) and
Caucasian (96%). Twenty one percent of the patients
were kidney transplant recipients. Median plasma PTH
level was 8.7 pmol/l. By definition the median PTH level
and the number of patients with PTH exceeding recom-
mended levels were significantly different between the
two treatment centers (Table 1).
Management of hyperparathyroidism
Table 2 shows the treatment characteristics of patients
in the year before entry in the MASTERPLAN study.
Three patients from center A were excluded from this
analysis and 18 patients from center B, because they
were under specialist physician care for less than six
months at MASTERPLAN baseline. In center A patients
visited their physicians more often, and more laboratory
tests were performed, although the number of PTH tests
was not significantly different. In center A more differ-
ent nephrologists and general internists were involved in
the patient’s treatment. PTH levels were not measured
in 29-39% of patients in the six-twelve months before
the start of MASTERPLAN. Of the patients with known
PTH levels 29 patients in center A and 27 patients in
center B had a PTH level exceeding recommended
levels. There was no significant difference in the way
that center A and center B handled the patients with
PTH exceeding recommended levels (Table 2). Specific-
ally, hyperparathyroidism resulted in a change in therapy
in less than 25% of patients.
Determinants of PTH
Correlation analyses showed that cause of kidney dis-
ease (p = 0.03), kidney transplant status (p < 0.001),
income (p = 0.02), serum calcium (p = 0.03), serum
phosphate (p < 0.001), eGFR (p < 0.001), treatment
center (p < 0.001), and furosemide use (p = 0.01) were
potential determinants of PTH (Table 3). As shown
in Table 1, distribution of cause of kidney disease,
kidney transplant status, and eGFR by MDRD-4 dif-
fered significantly between the two centers.
The factors that were univariately associated with
plasma PTH were all included in multivariate analyses.
Potential confounders that were also included were age,
sex, race, history of DM, BMI, smoking status, protein-
uria, thiazide use, and season of blood draw. Although
alphacalcidol and/or calciumcarbonate use and number
of drugs were positively correlated with PTH, they were
not included in multivariate models because of reverse
causation (patients who have higher PTH levels more
often use alphacalcidol, however the drug does not lead
to higher PTH levels).
Table 4 shows the results of multivariate linear regres-
sion analysis by which determinants of PTH were identi-
fied. Kidney transplant status, MDRD-4, and treatment
center were independent predictors of plasma PTH
level.
Role of GFR
Glomerular filtration rate is a well known determinant
of PTH. Various methods can be used to estimate GFR.
Since there were significant differences between center
A and B in serum urea and albumin, we considered that
MDRD-6 (which includes these variables) might give a
better estimation of GFR than MDRD-4 and subse-
quently predict plasma PTH level more accurately. Esti-
mated GFR by MDRD-6 was 37.7 (SD 12.0) for center A
and 37.0 ml/min/1.73 m2 (SD 12.2) for center B,
p = 0.69. Table 4 shows that, while the explained variance
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increased, the center effect was reduced when MDRD-6
instead of MDRD-4 was used in the model. We also
used the CKD-EPI equation, but this did not improve
the model, nor reduced the center effect (data not
shown).
Serum creatinine is an important parameter in the
MDRD formulas. After conversion of serum creatinine
to enzymatic values, mean eGFR by MDRD-6 was
35.7 ml/min/1.73 m2 in center A and 42.1 ml/min/
1.73 m2 in center B (p = 0.002).
We subsequently used MDRD-6 after creatinine con-
version in multivariate analysis, and found that treat-
ment center was no longer a significant predictor of
PTH (Table 4).
Since attainment of the PTH treatment target not only
depends on PTH, but also on eGFR, we extended the
Table 1 Characteristics of study population
Center A (n = 101) Center B (n = 100) p
Plasma PTH (pmol/l) 9.9 [6.7-15.5] 6.5 [3.6-11.0] <0.001
PTH exceeding recommended levels 67 (66%) 34 (34%) <0.001
Age (years) 52.2 (12.7) 58.8 (11.8) <0.001
Male sex 68 (67%) 75 (75%) 0.23
Caucasian race 99 (98%) 93 (93%) 0.09
Cause of kidney disease <0.001
Glomerulonephritis 34 (34%) 17 (17%)
Diabetic nephropathy 9 (9%) 4 (4%)
Renovascular 4 (4%) 15 (15%)
Interstitial nephritis 25 (25%) 6 (6%)
Congenital (including PKD) 20 (20%) 5 (5%)
Different/unknown 9 (9%) 53 (53%)
Kidney transplant recipient 33 (33%) 9 (9%) <0.001
History of diabetes mellitus 20 (20%) 13 (13%) 0.19
Income (euros/month) 2108 (489) 2030 (482) 0.26
BMI (kg/m2) 27.0 (5.0) 28.6 (4.5) 0.01
Smoking 15 (15%) 19 (19%) 0.43
Serum calcium (mmol/l) 2.40 (0.13) 2.40 (0.12) 0.71
Serum phosphate (mmol/l) 1.06 (0.25) 1.01 (0.22) 0.15
Serum urea (mmol/l) 13.5 [10.1-17.6] 9.8 [7.2-15.2] <0.001
Serum albumin (g/l) 39 (4) 42 (3) <0.001
Proteinuria (g/24 h) 0.6 [0.1-1.3] 0.3 [0.2-0.9] 0.10
Serum creatinine (μmol/l) 168 (53) 184 (60) 0.05
eGFR (MDRD-4, ml/min/1.73 m2) 40.3 (12.4) 36.3 (11.1) 0.02
Alphacalcidol use 16 (16%) 13 (13%) 0.57
Calciumcarbonate use 13 (13%) 5 (5%) 0.05
Alphacalcidol and/or calciumcarbonate use 21 (21%) 16 (16%) 0.38
Furosemide use 17 (17%) 9 (9%) 0.10
Thiazide use 22 (22%) 46 (46%) <0.001
Number of drugs 5.82 (3.90) 5.73 (2.85) 0.85
Season of blood draw 0.34
Winter 21 (21%) 15 (15%)
Spring 24 (24%) 17 (17%)
Summer 24 (24%) 30 (30%)
Fall 32 (32%) 38 (38%)
Values are given as mean (SD), n (%), or median [interquartile range].
PTH: parathyroid hormone; PKD: polycystic kidney disease; BMI: body mass index; eGFR: estimated glomerular filtration rate; MDRD: modification of diet in renal
disease.
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multivariate analyses to determine predictors of meeting
the PTH treatment target. The results were similar as
reported in Table 4 (data not shown).
Discussion
In our study we compared two hospitals that differed in
the attainment of the PTH treatment goal and explored
possible explanations. We showed that the apparent dif-
ferences were explained by incomparable patient popula-
tions and laboratory techniques, and the use of the
abbreviated MDRD formula to estimate GFR. After cor-
rection for kidney transplant status and with the use of
the MDRD-6 formula with calibrated creatinine to esti-
mate GFR, treatment center no longer influenced the at-
tainment of the PTH treatment goal.
We evaluated potential differences in treatment which
might explain any difference in attainment of the PTH
target. We focused on characteristics of the treatment
given to patients in the year before the start of the MAS-
TERPLAN study. Plantinga et al. have shown that more
frequent patient-physician contacts in patients with end-
stage renal disease are positively associated with the
achievement of clinical performance targets, including
targets of bone and mineral disorder [30]. One would
therefore expect that patients in center A, the ‘worst
performing’ hospital, visited their physician less often
and had less laboratory tests done. Table 2 shows that
the opposite was true. Admittedly, the number of visits
and laboratory tests may be dictated by patient morbid-
ity and disease history and not necessarily reflect QoC,
e.g. kidney transplant recipients in general need more
frequent control. In addition, there were no differences
in the way both centers handled the patients with PTH
values exceeding recommended levels.
Table 2 also shows that relatively few PTH tests were
performed, while PTH is one of the most deviant labora-
tory values in CKD patients. In both centers in only a
small number of patients with PTH exceeding recom-
mended levels, treatment was adjusted or started. Thus,
although guidelines give attention to treatment of CKD-
bone and mineral disease, and although treatment tar-
gets are well defined, physicians are insufficiently aware
of the importance of adequate treatment of hyperpara-
thyroidism: our data point to therapeutic inertia towards
the PTH treatment target.
In univariate analysis several factors were potential
determinants of PTH. Multivariate analyses showed that
many of these factors did not independently predict
PTH levels. Renal function on the basis of calibrated
creatinine values and kidney transplant status are the
most important determinants of attainment of the PTH
treatment target.
As mentioned before, GFR is a well known determin-
ant of PTH and increases in PTH occur early in the
Table 2 Characteristics of treatment in the year before MASTERPLAN baseline in center A and B
Center A (n= 98) Center B (n = 82) p
No. of patient visits 6.73 (6.21) 3.11 (1.41) <0.001
No. of different nephrologists/ internists 1.92 (1.63) 1.10 (0.30) <0.001
No. of patient letters written 0.70 (0.48) 0.65 (0.51) 0.43
No. of laboratory tests
Serum calcium 4.05 (4.31) 2.39 (1.77) 0.001
Serum phosphate 3.97 (4.14) 2.30 (1.68) 0.001
Plasma PTH 0.92 (1.48) 1.01 (0.88) 0.61
Serum creatinine 8.59 (9.80) 5.32 (4.24) 0.01
PTH level known 60 (61%) 58 (71%) 0.18
PTH exceeding recommended levels 29 (30%) (n = 60) 27 (47%) (n = 58) 0.85
If PTH was exceeding recommended levels (n = 29) (n = 27)
Already on medication 8 (28%) 6 (22%) 0.64
Adjustment of treatment 4 (14%) 2 (7%) 0.44
Start treatment 3 (10%) 4 (15%) 0.61
PTH still exceeding recommended levels at MASTERPLAN baseline 26 (90%) 21 (78%) 0.23
Change in serum creatinine (μmol/l) 1.1 (31.1) 8.2 (23.6) 0.09
Hospitalization (at least once) 22 (22%) 12 (15%) 0.18
Surgery (at least once) 13 (13%) 5 (6%) 0.11
Only patients who were under the care of a specialist physician (nephrologist or internist) for at least 6 months before the MASTERPLAN study were analyzed.
Values given are mean (SD) or n (%).
PTH: parathyroid hormone.
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course of renal insufficiency. We observed an inverse re-
lationship between PTH and eGFR (Table 3). Although
eGFR proved to be an important, independent predictor
of PTH, in the initial analysis the differences in PTH
levels between centers could not be explained by differ-
ences in eGFR. However, all formulas for estimating
GFR have limitations. We showed that MDRD-4 is in-
valid in patients with proteinuria, where MDRD-6
proved better [31]. MDRD-6 superiority was also shown
in kidney transplant recipients [32]. Since MDRD for-
mulas critically depend on the measurement of serum
creatinine, differences between serum creatinine assays
affect their performance. Therefore, recent guidelines
suggest to use calcibrated serum creatinine values [33].
Our data clearly show that the use of the MDRD-6
formula reduced the center effect. Moreover, when using
the MDRD-6 formula and calibrated serum creatinine
values, there were no longer significant differences in at-
tainment of PTH treatment targets between the centers.
From these findings we conclude that it is not always
valid to use the abbreviated MDRD formula instead of
the six-variable MDRD formula, especially in analyses in
which GFR plays a central role. Moreover, comparable
creatinine assays must always be used. Physicians should
be aware of the limitations of formulas for estimating
GFR, especially of the MDRD-4 formula, since this for-
mula is extensively used (in The Netherlands and also in
many other countries).
Admittedly, although the results may be explained by
the better performance of the MDRD-6 formula as
measure of real GFR, we cannot exclude that other fac-
tors are involved. The MDRD-6 formula incorporates
serum albumin concentration. It is known that there is
an inverse relationship between plasma calcidiol levels
and magnitude of proteinuria, and thus hypoalbumine-
mia, because of loss of vitamin D metabolites and vita-
min D binding protein in the urine in patients with
proteinuria [34,35]. Low plasma calcidiol levels are
related to higher PTH concentrations [36-39].
It is well known that hyperparathyroidism often per-
sists for many years after kidney transplantation [40,41].
Treatment with vitamin D compounds is complicated,
Table 3 Correlation between plasma (Ln)PTH levels and potential determinants of plasma PTH
r rs p
Age (years) -.10 0.16
Male sex -.01 0.89
Caucasian race -.07 0.34
Cause of kidney disease renovascular or different/unknown* -.15 0.03
Kidney transplant .27 <0.001
Diabetes mellitus .02 0.82
Income (euros/month) -.16 0.02
BMI (kg/m2) .00 0.99
Smoking .01 0.94
Serum calcium (mmol/l) -.16 0.03
Serum phosphate (mmol/l) .29 <0.001
(Ln)Proteinuria (g/24u) .12 0.08
Serum creatinine (μmol/l) .48 <0.001
eGFR (MDRD-4, ml/min/1.73 m2) -.48 <0.001
eGFR (MDRD-6, ml/min/1.73 m2) -.55 <0.001
Center A .27 <0.001
Alphacalcidol use .18 0.01
Calciumcarbonate use .17 0.02
Alphacalcidol and/or calciumcarbonate use .21 0.003
Furosemide use .19 0.01
Thiazide use -.01 0.87
Number of drugs 0.35 <0.001
Blood drawn in summer or fall* -.08 0.25
Ln: natural logarithm; PTH: parathyroid hormone; r: Pearson correlation coefficient; rs: Spearman’s rho correlation coefficient; BMI: body mass index; eGFR:
estimated glomerular filtration rate; MDRD: modification of diet in renal disease.
*Patients classified as having a renovascular or different/unknown cause of kidney disease on average had the lowest (Ln)PTH levels. Therefore these categories
were combined. The same holds for patients with blood drawn in summer or fall.
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since hyperparathyroidism in post-transplant patients is
usually associated with hypercalcemia [40]. Conse-
quently, mean PTH level was higher in kidney transplant
recipients and only a smaller number of kidney trans-
plant patients achieved the PTH treatment goal. In cen-
ter A more kidney transplant recipients were treated
than in center B.
Insight and transparency in QoC is becoming more and
more important. Various indicators are used to assess hos-
pital performance, for example attainment of treatment
targets, as in our study. Benchmarking has become a way
to compare and judge treatment centers. Ranking hospi-
tals on the basis of performance indicators is supposed to
give health care professionals, insurance companies as
well as (associations of) patients insight in QoC. The
results of our study question the reliability of these rank-
ings and other hospital performance comparisons.
There are several difficulties associated with hospital
performance comparisons: definitions are not always the
same [16,42], laboratory assays vary [18], data quality is
variable between hospitals and even within one hospital
[16,42,43]. Another problem is patient case mix
[16,18,42,43]. Patient age, race, severity of illness, and
comorbidity all influence the outcome of care. Retro-
spective risk adjustment can only partly adjust for all
these factors. There will always be additional residual
confounding [42,43]. Moreover, random variation has to
be taken into account [16,42-45]. Therefore, when de-
scribing results of hospital performance comparisons,
confidence intervals should be provided to give insight
into the influence of random variation [16,44]. The prac-
tice of summarizing several performance indicators in
one composite score adds to the unreliability of per-
formance measures since small differences in methods
of constructing the composite score can have substantial
impact on the results [44]. Finally, whether performance
indicators provide a true reflection of QoC is question-
able. Performance indicators represent mainly technical
aspects, while the humane side of health care and trad-
itional components of caring, essential when talking
about QoC, are ignored [46,47].
A major limitation of our study is that we compared
only two hospitals. The extent to which the findings can
be generalized beyond the centers and cases studied, is
unknown. Another limitation is the lack of plasma calci-
diol levels. Since plasma calcidiol and PTH are inversely
related [36-39], differences in calcidiol levels can have
important consequences for PTH concentrations. Other
unknown, and possibly influencing, factors are patient
compliance, FGF-23 levels, and dietary intake of calcium,
phosphate, protein and vitamin D, including over-the-
counter vitamin pills.
Conclusions
In conclusion, the observed differences in hospital per-
formance on PTH management between center A and
center B in patients with CKD are explained by incom-
parable patient populations and laboratory techniques,
Table 4 Multivariate linear regression (backward) analyses on predictors of plasma (Ln)PTH level
eGFR calculated with Model with or without
treatment center




Including treatment center R2 = 0.42 Center 0.49 [0.31-0.68]
Kidney transplant 0.55 [0.33-0.78]
eGFR (MDRD-4) −0.04 [−0.05 - -0.03]
Without treatment center R2 = 0.34 Kidney transplant 0.72 [0.48-0.95]
eGFR (MDRD-4) −0.04 [−0.04 - -0.03]
MDRD-6 before creatinine
conversion
Including treatment center R2 = 0.45 Center 0.36 [0.19-0.54]
Kidney transplant 0.54 [0.32-0.76]
eGFR (MDRD-6) −0.04 [−0.05 - -0.03]
Without treatment center R2 = 0.40 Kidney transplant 0.67 [0.46-0.89]
eGFR (MDRD-6) −0.04 [−0.05 - -0.03]
MDRD-6 after creatinine
conversion
Including treatment center R2 = 0.45 Center 0.13 [−0.05-0.31]
Kidney transplant 0.54 [0.32-0.76]
eGFR (MDRD-6) −0.03 [−0.04 - -0.03]
Without treatment center R2 = 0.44 Kidney transplant 0.59 [0.38-0.79]
eGFR (MDRD-6) −0.03 [−0.04 - -0.03]
The difference in R2 between the model with and without treatment center illustrates the contribution of the treatment center to the explained variance. The
linear regression coefficient reflects the association between the independent predictor and (Ln)PTH. eGFR is a very important determinant, since for every extra
ml filtration per minute, PTH decreases by three percent (based on the final model using MDRD-6 after creatinine conversion).
Ln: natural logarithm; PTH: parathyroid hormone (pmol/l); eGFR: estimated glomerular filtration rate (ml/min/1.73 m2); MDRD: modification of diet in renal disease;
CI: confidence interval.
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and use of the abbreviated MDRD formula to estimate
GFR. We propose the use of the MDRD-6 formula to es-
timate GFR in analyses when variables are critically
dependent on glomerular filtration rate. Our study
shows that great caution is required in interpreting the
results of hospital performance comparisons. Uncritical
use of these measures can result in treatment centers
being wrongly classified in terms of performance.
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